CAT-152 lerdelimumab human anti-TGF-beta-2 monoclonal antibody: Phase II completed

CAT said that CAT-152 was safe and well tolerated in a placebo-controlled U.K. Phase II trial in 56 patients, but no difference in intraocular pressure (IOP), the secondary endpoint, was shown. IOP wa...